Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T09:08:29.843Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychiatric shades of grey: mirtazapine-induced hair discoloration and hair loss

Published online by Cambridge University Press:  02 February 2016

M. Osman  and
M. D. McCauley
M. Osman*
Affiliation:
St Brigid’s Hospital, Ardee, Co. Louth, Ireland
M. D. McCauley
Affiliation:
St Brigid’s Hospital, Ardee, Co. Louth, Ireland
*
*Address for correspondence: Dr M. Osman, MBBS, MRCPsych, M.Sc., St Brigid’s Hospital, Ardee, Co. Louth, Ireland. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction

Mirtazapine is indicated in the treatment of major depressive disorder particularly in selective serotonin re-uptake inhibitors resistance. Its effect on hair loss is rare with no previous documented effect on hair colour.

Method

Review of relevant literature and description of a case report of a 54-year-old male patient who developed alopecia and hair discoloration after initiation of mirtazapine treatment.

Results

Upon cessation of mirtazapine treatment full restoration of hair colour and regrowth of hair was attained within 10 weeks.

Discussion

There was clear temporal relationship between experiencing hair loss and commencing mirtazapine treatment. No other more likely medical reason to explain such experience was established. A noticeable restoration of the hair colour occurred following mirtazapine cessation.

Conclusion

Mirtazapine is associated with hair discoloration and hair loss. The possibility of such distressing adverse effects needs to be conveyed to patients by clinicians and to be further explored by researchers.

Keywords

Adverse effectsalopeciadepressive disorderhair discolourationmirtazapine
Type
Case Report
Information
Irish Journal of Psychological Medicine , Volume 33 , Issue 3 , September 2016 , pp. 175 - 178
Copyright
© College of Psychiatrists of Ireland 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bublin, JG, Thompson, DF (1992). Drug-induced hair colour changes. Journal of Clinical Pharmacy and Therapeutics 17, 297–302.Google Scholar
Chiu, HW, Li, TC (2011). Rapid weight gain during mirtazapine treatment. Journal of Neuropsychiatry and Clinical Neuroscience 23, E7.Google Scholar
Donovan, JC, Price, VH (2010). Images in clinical medicine. Chloroquine-induced hair hypopigmentation. The New England Journal of Medicine 363, 372.CrossRefGoogle ScholarPubMed
Frum, Y, Eccleston, GM, Meidan, VM (2008). Factors influencing hydrocortisone permeation into human hair follicles: use of the skin sandwich system. Intenational Journal of Pharmaceutics 358, 144–150.Google Scholar
Joint Formulary Committee. British National Formulary (2014). BMJ Group and Pharmaceutical Press: London, UK, issue 68, September 2014–March 2015, 256pp.Google Scholar
Kent, JM (2000). SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355, 911–918.CrossRefGoogle ScholarPubMed
Lin, CH, Hsu, CW, Lin, CH, Lane, HY (2010). A case of mirtazapine-associated hair loss. The Journal of Clinical Psychiatry 71, 1400–1401.CrossRefGoogle ScholarPubMed
Llau, ME, Viraben, R, Montastruc, JL (1995). Drug-induced alopecia: review of the literature. Therapie 50, 145–150.Google Scholar
Mercke, Y, Sheng, H, Khan, T, Lippmann, S (2000). Hair loss in psychopharmacology. Annals of Clinical Psychiatry 12, 35–42.Google Scholar
Schneider, MR, Schmidt-Ullrich, R, Paus, R (2009). The hair follicle as a dynamic miniorgan. Current Biology 19, R132–R142.Google Scholar
Taylor, D, Paton, C, Kapur, S (2012). The Maudsley Prescribing Guidelines in Psychiatry, 11th edn. Wiley-Blackwell Publishing: West Sussex, UK, 155pp.Google Scholar
Thase, ME, Nierenberg, AA, Vrijland, P, van Oers, HJ, Schutte, AJ, Simmons, JH (2010). Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. International Clinical Psychopharmacology 25, 189–198.Google Scholar
Tosti, A, Misciali, C, Piraccini, BM, Peluso, AM, Bardazzi, F (1994). Drug-induced hair loss and hair growth. Drug Safety 10, 310–317.CrossRefGoogle Scholar
van den Bemt, PM, Brodie-Meijer, CC, Krijnen, RM, Nieboer, C (1999). Ziekenhuisapotheek Medisch Centrum Leeuwarden/Apotheek Ziekenhuis De Tjongerschans Heerenveen [Drug induced alopecia]. Nederlands Tijdschrift Voor Geneeskunde 143, 990–994.Google Scholar
Van Neste, D, Tobin, DJ (2004). Hair cycle and hair pigmentation: dynamic interactions and changes associated with aging. Micron 35, 193–200.Google Scholar
Watanabe, N, Omori, IM, Nakagawa, A, Cipriani, A, Barbui, C, Churchill, R, Furukawa, TA (2011). Mirtazapine versus other antidepressive agents for depression. Cochrane Database Systematic Reviews 7, CD006528.Google Scholar